Found: 4 articles
Article | Edition |
---|---|
A.V. Fateeva, E.V. Eliseeva, V.I. Apanasevich, A.A. Zaemskaya
Analysis of pharmacotherapy in patients with HR+HER2- metastatic breast cancer with PIK3CA mutations in real clinical practice
|
№7 / 2024 |
Gordeeva O.O.
Assessing the risk of recurrence of luminal HER2-negative breast cancer and the possibility of intensifying adjuvant hormonal therapy to reduce the risk of progression
|
№6 / 2024 |
K.S. Grechukhina (1, 2), K.A. Vorontsova (1), T.M. Kuko (1), A.A. Prosvirnov (1), I.P. Ganshina (3), E.V. Lubennikova (3), I.V. Kolyadina (4, 5), L.G. Zhukova (1)
Abemacyclib is a unique representative of the class of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer
|
№7 / 2021 |
L.G. Zhukova, E.I. Chichikov, O.O. Gordeeva, D.A. Filonenko
PALBOCICLIB – NEW POSSIBILITIES OF THERAPY OF HORMON-POSITIVE HER2-NEGATIVE BREAST CANCER
|
№17 / 2017 |